- Home
- JANX vs PCH Comparison
JANX vs PCH Comparison
Compare JANX & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- PCH
- Stock Information
- Founded
- JANX 2017
- PCH 1903
- Country
- JANX United States
- PCH United States
- Employees
- JANX N/A
- PCH N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- PCH Real Estate Investment Trusts
- Sector
- JANX Health Care
- PCH Real Estate
- Exchange
- JANX Nasdaq
- PCH Nasdaq
- Market Cap
- JANX 1.4B
- PCH 3.0B
- IPO Year
- JANX 2021
- PCH N/A
- Fundamental
- Price
- JANX $24.06
- PCH $40.69
- Analyst Decision
- JANX Strong Buy
- PCH Strong Buy
- Analyst Count
- JANX 7
- PCH 7
- Target Price
- JANX $94.29
- PCH $48.43
- AVG Volume (30 Days)
- JANX 659.3K
- PCH 525.1K
- Earning Date
- JANX 08-06-2025
- PCH 07-28-2025
- Dividend Yield
- JANX N/A
- PCH 4.42%
- EPS Growth
- JANX N/A
- PCH 7.03
- EPS
- JANX N/A
- PCH 0.61
- Revenue
- JANX $9,336,000.00
- PCH $1,102,209,000.00
- Revenue This Year
- JANX N/A
- PCH $2.91
- Revenue Next Year
- JANX $1,470.82
- PCH $4.67
- P/E Ratio
- JANX N/A
- PCH $67.06
- Revenue Growth
- JANX 28.12
- PCH 10.86
- 52 Week Low
- JANX $22.48
- PCH $36.82
- 52 Week High
- JANX $71.71
- PCH $48.12
- Technical
- Relative Strength Index (RSI)
- JANX 48.08
- PCH 59.54
- Support Level
- JANX $22.74
- PCH $37.92
- Resistance Level
- JANX $24.73
- PCH $39.62
- Average True Range (ATR)
- JANX 1.26
- PCH 1.04
- MACD
- JANX 0.09
- PCH 0.16
- Stochastic Oscillator
- JANX 47.35
- PCH 93.82
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.